Biogen Idec Stockholders Elect Company's Board Nominees

Thursday, June 19, 2008 9:44 am EDT

Dateline:

CAMBRIDGE, Mass.

Public Company Information:

NASDAQ:
BIIB

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB) today announced that, based on a preliminary count provided by its proxy solicitor, stockholders have elected all four of the Companys nominees Cecil B. Pickett, Ph.D., Lynn Schenk, J.D., Phillip A. Sharp, Ph.D., and Stelios Papadopoulos, Ph.D. to the Biogen Idec Board of Directors at todays Annual Meeting of Stockholders. In addition, based on that preliminary count, the proposal to amend the Companys bylaws to set the size of the Board at 12 has been defeated. The preliminary count is subject to the official tabulation of vote results, which will be provided by Biogen Idecs independent inspector of elections, IVS Associates, Inc., in approximately 2-3 weeks.

Bruce R. Ross, Biogen Idecs Chairman, said, We are gratified that our nominees will serve on the Biogen Idec Board of Directors. Our Board has a track record of delivering stockholder value and is committed to pursuing all avenues to continue to do so in the future. We look forward to turning our undivided attention to delivering strong performance and growing our business for stockholders.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Contact:

Biogen Idec Media Contact:
Naomi Aoki, 617-914-6524
Director, Public Affairs
or
Biogen Idec Investor Relations Contact:
Elizabeth Woo, 617-679-2812
Vice President, Investor Relations